Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)
| Market Cap | $12.80M+3.6% |
| Revenue (ttm) | $2.53M-51.3% |
| Net Income | -$26.02M+39.0% |
| EPS | -$14.53-63.4% |
| Shares Out | 2.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Aug 29, 2014 |
| Volume | 60,465 |
| Open | $5.10 |
| Previous Close | $5.06 |
| Day's Range | $4.88 - $5.21 |
| 52-Week Range | $3.10 - $7.78 |
| Beta | 1.01 |
| Analysts | Hold |
| Price Target | $4.00(-18.53%) |
| Earnings Date | Mar 11, 2027 |
About BOLT
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 11, 2027Earnings report
$BOLT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BOLT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BOLT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BOLT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BOLT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BOLT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BOLT
| VXFVanguard Extended Market ETF | $46.53K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BOLT’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 results reported but limited detail provided; insufficient coverage to assess whether results beat or missed expectations.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 22Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
